Form 4: NeuroPace Executive Adjusts Holdings

NeuroPace Inc. reports a transaction involving Chief Medical Officer Martha Morrell's beneficial ownership of common stock.

Summary

• Martha Morrell, Chief Medical Officer of NeuroPace Inc., reported a transaction on June 24, 2026.
• This transaction involved 335 shares of common stock.
• The shares were acquired at a price of $16.22 per share.
• These shares were withheld by the Issuer to satisfy tax withholding obligations related to the vesting of a restricted stock unit award.
• Following this transaction, Martha Morrell beneficially owns 52,050 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine executive stock transaction for tax purposes and does not indicate significant changes in beneficial ownership or company strategy.

Positives

• Martha Morrell's beneficial ownership of NeuroPace Inc. common stock remains substantial at 52,050 shares.
• The transaction reflects the vesting of restricted stock units, indicating continued equity-based compensation for a key executive.

Negatives

• The transaction involved the withholding of shares to cover tax obligations, which reduces the net shares available to the executive.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executive stock transactions and do not typically provide strategic insights. This filing indicates standard equity compensation practices within the biotechnology sector.

Stakeholder Impact

• Shareholders: No immediate impact expected as this is a standard tax-related transaction for an executive.

Key Dates

Keywords

NeuroPace Inc., NPCE, Form 4, Beneficial Ownership, Martha Morrell, Chief Medical Officer, Common Stock, Restricted Stock Unit, Tax Withholding